Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease
April 04, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 4, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Raises $5.0 Million in Equity Financing
April 03, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 3, 2023 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Reports Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 01:00 ET
|
Addex Therapeutics
CHF 7.0M ($ 7.4M) of cash and cash equivalents at December 31, 2022ADX71149 Phase 2 study in epilepsy cohort 1 completes part 1 – independent interim review committee (IRC) recommendation expected...
Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
March 28, 2023 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, March 28, 2023 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex Announces Upcoming Conferences it will participate for H1 2023
March 16, 2023 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, March 16, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Regains Nasdaq Listing Compliance
February 09, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 9, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1
February 06, 2023 01:00 ET
|
Addex Therapeutics
Data to be reviewed by independent interim review committee (IRC) to keep study blinded Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 6, 2023 - Addex...
Addex Provides Corporate Update and Financial Guidance
January 19, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
December 08, 2022 01:00 ET
|
Addex Therapeutics
Addex to receive USD 1 million in additional research fundingCollaboration continues to advance through drug candidate selection phase Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland,...
Addex Reports Q3 2022 Financial Results and Provides Corporate Update
November 11, 2022 01:00 ET
|
Addex Therapeutics
CHF10.4M ($10.4M) of cash and cash equivalents at September 30, 2022Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR ...